Corporate
ENDECE, LLC, (ENDECE) is dedicated to discovering and developing small molecules that provide an improved quality of life for patients diagnosed with debilitating disorders with few therapeutic options. ENDECE’s pipeline of products is designed to treat cancers with low five-year survival rates (including pancreas and lung), neurodegenerative autoimmune diseases (e.g. MS), and pain.
More Info »
Products
ENDECE has discovered a platform of over 40 proprietary compounds that act as agonists towards estrogen receptors. A subset of ENDECE’s compounds are known to bind specific estrogen receptors and do not bind to androgen, progesterone or glucocorticoid receptors. This subset of compounds varies greatly in their binding affinity and functional activity and as such are being assessed and developed for a multitude of human diseases.
More Info »
